Orbis Allan Gray LTD Amgen Inc Transaction History

Orbis Allan Gray LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$180.87 - $203.88 $45.6 Million - $51.3 Million	-251,860 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$178.4 - $208.25 $2.07 Million - $2.41 Million	-11,591 Reduced 4.4%	251,860 $49 Million
Q3 2018 Nov 14, 2018	BUY	$185.29 - $208.89 $51,695 - $58,280	279 Added 0.11%	263,451 $54.6 Million
Q2 2018 Aug 14, 2018	SELL	$166.05 - $186.51 $19,926 - $22,381	-120 Reduced 0.05%	263,172 $48.6 Million
Q1 2018 May 15, 2018	SELL	$169.43 - $198.0 $6.22 Million - $7.27 Million	-36,734 Reduced 12.24%	263,292 $44.9 Million
Q4 2017 Feb 14, 2018	BUY	$168.79 - $188.59 $6,582 - $7,355	39 Added 0.01%	300,026 $52.2 Million
Q3 2017 Nov 14, 2017	BUY	$167.29 - $191.0 $50.2 Million - $57.3 Million	299,987	299,987 $55.9 Million

3,122

410M

7.56M

7.2M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $158B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Orbis Allan Gray LTD, based on Form 13F filings with the SEC.

Stay updated on Orbis Allan Gray LTD with notifications on news.